Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 518 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 373 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
10.02. | NLS und Kadimastem planen Fusion für Innovation in der Diabetesbehandlung | 1 | Investing.com Deutsch | ||
KADIMASTEM Aktie jetzt für 0€ handeln | |||||
31.01. | Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics | 969 | PR Newswire | ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
30.12.24 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger | 521 | PR Newswire | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform... ► Artikel lesen | |
19.12.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment | 352 | ACCESS Newswire | This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS... ► Artikel lesen | |
04.11.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement | 492 | ACCESS Newswire | ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem")... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,770 | -2,35 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
BIONTECH | 92,25 | -0,54 % | BioNTech-Aktie vor nächster Rallye? Auf diese 2 Dinge warten jetzt alle Anleger | Nach der Corona-Zeit wartet die BioNTech-Aktie weiter auf den nächsten großen Durchbruch. Eine neue Rallye an der Börse könnte aber nicht mehr lange auf sich warten lassen. Das Corona-Momentum, dass... ► Artikel lesen | |
EVOTEC | 6,950 | -1,36 % | Evotec Aktie kämpft sich zurück: Wie stabil ist der Anstieg? | Die Evotec Aktie hat einen großen Teil des Kurssturzes vom vergangenen Montag wettgemacht und zeigt sich zum Wochenstart stabilisiert. Am Freitag legte die Biotech-Aktie kräftig zu und schloss bei 7... ► Artikel lesen | |
MODERNA | 23,840 | -0,10 % | Moderna erhält EU-Zulassung für aktualisierten COVID-19-Impfstoff | Moderna hat von der Europäischen Kommission die Zulassung für die aktualisierte Version seines COVID-19-Impfstoffs Spikevax erhalten. Die neue Formulierung richtet sich gegen die SARS-CoV-2-Variante... ► Artikel lesen | |
4D MOLECULAR THERAPEUTICS | 6,440 | +43,11 % | Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26.
4D... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,675 | -4,62 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
AVIDITY BIOSCIENCES | 35,900 | -2,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
ADMA BIOLOGICS | 19,335 | +3,40 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
ITEOS THERAPEUTICS | 10,090 | -0,44 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 27,090 | +2,73 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
MOONLAKE IMMUNOTHERAPEUTICS | 52,91 | +5,11 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
BEAM THERAPEUTICS | 18,830 | -4,46 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
IMMUNOVANT | 15,690 | -2,30 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
DYNE THERAPEUTICS | 10,050 | +2,03 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,850 | +5,20 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 |